Detalhe da pesquisa
1.
Immune checkpoint inhibitor for hepatocellular carcinoma recurrence after liver transplantation.
Hepatobiliary Pancreat Dis Int;
19(1): 91-93, 2020 Feb.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31706859
2.
Trastuzumab, not lapatinib, has therapeutic effects on Chinese patients with HER2-positive cholangiocarcinoma.
Hepatobiliary Pancreat Dis Int;
17(5): 477-479, 2018 Oct.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30262418
3.
Pemigatinib in previously treated Chinese patients with locally advanced or metastatic cholangiocarcinoma carrying FGFR2 fusions or rearrangements: A phase II study.
Cancer Med;
12(4): 4137-4146, 2023 02.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36127767
4.
[Evaluation of interferon-gamma producing-cells using enzyme linked immunospot assay in mice model of acute graft versus host disease].
Zhejiang Da Xue Xue Bao Yi Xue Ban;
35(4): 397-402, 2006 07.
Artigo
em Zh
| MEDLINE
| ID: mdl-16924704
5.
TGF-beta1 treated murine dendritic cells are maturation resistant and down-regulate Toll-like receptor 4 expression.
J Zhejiang Univ Sci;
5(10): 1239-44, 2004 Oct.
Artigo
em Inglês
| MEDLINE
| ID: mdl-15362195
6.
Phase II trial of gefitinib in pretreated Chinese women with advanced non-small-cell lung cancer.
Med Oncol;
29(2): 595-9, 2012 Jun.
Artigo
em Inglês
| MEDLINE
| ID: mdl-21399997
7.
Characteristic CYP2A6 genetic polymorphisms detected by TA cloning-based sequencing in Chinese digestive system cancer patients with S-1 based chemotherapy.
Oncol Rep;
27(5): 1606-10, 2012 May.
Artigo
em Inglês
| MEDLINE
| ID: mdl-22322240
8.
Phase II study of FOLFIRI regimen in patients with advanced colorectal cancer refractory to fluoropyrimidine and oxaliplatin.
Cancer Chemother Pharmacol;
67(1): 147-52, 2011 Jan.
Artigo
em Inglês
| MEDLINE
| ID: mdl-20221830
9.
[Effects of transforming growth factor beta1 on dendritic cells function].
Zhonghua Xue Ye Xue Za Zhi;
25(8): 449-52, 2004 Aug.
Artigo
em Zh
| MEDLINE
| ID: mdl-15555257